98 research outputs found
Quality of Life and Costs in Parkinson's Disease: A Cross Sectional Study in Hungary.
BACKGROUND: Patient reported outcomes and costs of illness are useful to capture some of the multiple effects of a disease and its treatments. Our aim was to assess quality of life (QoL) and costs of Parkinson's disease (PD) in Hungary, and to analyze their associations. METHODS: A cross-sectional questionnaire survey was conducted in one neurology university clinic. Clinical characteristics, PD related resource utilizations and productivity loss in the past 12 months were recorded; the Hoehn&Yahr (HY) scale, PDQ-39 and EQ-5D questionnaires were applied. Cost calculation was performed from the societal perspective. RESULTS: 110 patients (34.5% female) were involved with mean age of 63.3 (SD = 11.3) and disease duration of 8.2 (SD = 5.8) years. PDQ-39 summary score was 48.1 (SD = 13.4). The average EQ-5D score was 0.59 (SD = 0.28), and was significantly lower than the population norm in age-groups 45-74. The correlation was significant between EQ-5D and PDQ-39 (-0.47, p = 0.000), the HY scale and EQ-5D (-0.3416, p = 0.0008) and PDQ-39 (0.3419, p = 0.0006) scores. The total mean cost was euro6030.2 (SD = 6163.0)/patient/year (direct medical 35.7%, direct non-medical 29.4%, indirect cost 34.9%). A one year increase in disease duration and 0.1 decrease of the EQ-5D utility score increase the yearly costs by 8 to 10%, and 7.8%, respectively. The effect of the PDQ-39 score on total cost was not significant. CONCLUSIONS: Disease severity and public health importance of PD are clearly demonstrated by the magnitude of QoL loss. PD-related costs are substantial, but are much lower in Hungary than in Western European countries. Disease duration and EQ-5D score are significant proxy of costs
Animal perception in gravel-bed rivers: scales of sensing and environmental controls on sensory information
Herbal Medicines for Parkinson's Disease: A Systematic Review of Randomized Controlled Trials
OBJECTIVE: We conducted systematic review to evaluate current evidence of herbal medicines (HMs) for Parkinson's disease (PD). METHODS: Along with hand searches, relevant literatures were located from the electronic databases including CENTRAL, MEDLINE, EMBASE, CINAHL, AMED, PsycInfo, CNKI, 7 Korean Medical Databases and J-East until August, 2010 without language and publication status. Randomized controlled trials (RCTs), quasi-randomized controlled trials and randomized crossover trials, which evaluate HMs for idiopathic PD were selected for this review. Two independent authors extracted data from the relevant literatures and any disagreement was solved by discussion. RESULTS: From the 3432 of relevant literatures, 64 were included. We failed to suggest overall estimates of treatment effects on PD because of the wide heterogeneity of used herbal recipes and study designs in the included studies. When compared with placebo, specific effects were not observed in favor of HMs definitely. Direct comparison with conventional drugs suggested that there was no evidence of better effect for HMs. Many studies compared combination therapy with single active drugs and combination therapy showed significant improvement in PD related outcomes and decrease in the dose of anti-Parkinson's drugs with low adverse events rate. CONCLUSION: Currently, there is no conclusive evidence about the effectiveness and efficacy of HMs on PD. For establishing clinical evidence of HMs on PD, rigorous RCTs with sufficient statistical power should be promoted in future
Place of death of people living with Parkinson’s disease: a population-level study in 11 countries
Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.
BACKGROUND: Neurological disorders are now the leading source of disability globally, and ageing is increasing the burden of neurodegenerative disorders, including Parkinson's disease. We aimed to determine the global burden of Parkinson's disease between 1990 and 2016 to identify trends and to enable appropriate public health, medical, and scientific responses. METHODS: Through a systematic analysis of epidemiological studies, we estimated global, regional, and country-specific prevalence and years of life lived with disability for Parkinson's disease from 1990 to 2016. We estimated the proportion of mild, moderate, and severe Parkinson's disease on the basis of studies that used the Hoehn and Yahr scale and assigned disability weights to each level. We jointly modelled prevalence and excess mortality risk in a natural history model to derive estimates of deaths due to Parkinson's disease. Death counts were multiplied by values from the Global Burden of Disease study's standard life expectancy to compute years of life lost. Disability-adjusted life-years (DALYs) were computed as the sum of years lived with disability and years of life lost. We also analysed results based on the Socio-demographic Index, a compound measure of income per capita, education, and fertility. FINDINGS: In 2016, 6·1 million (95% uncertainty interval [UI] 5·0-7·3) individuals had Parkinson's disease globally, compared with 2·5 million (2·0-3·0) in 1990. This increase was not solely due to increasing numbers of older people, because age-standardised prevalence rates increased by 21·7% (95% UI 18·1-25·3) over the same period (compared with an increase of 74·3%, 95% UI 69·2-79·6, for crude prevalence rates). Parkinson's disease caused 3·2 million (95% UI 2·6-4·0) DALYs and 211 296 deaths (95% UI 167 771-265 160) in 2016. The male-to-female ratios of age-standardised prevalence rates were similar in 2016 (1·40, 95% UI 1·36-1·43) and 1990 (1·37, 1·34-1·40). From 1990 to 2016, age-standardised prevalence, DALY rates, and death rates increased for all global burden of disease regions except for southern Latin America, eastern Europe, and Oceania. In addition, age-standardised DALY rates generally increased across the Socio-demographic Index. INTERPRETATION: Over the past generation, the global burden of Parkinson's disease has more than doubled as a result of increasing numbers of older people, with potential contributions from longer disease duration and environmental factors. Demographic and potentially other factors are poised to increase the future burden of Parkinson's disease substantially
Epidemiology of neurodegenerative diseases in sub-Saharan Africa: a systematic review
BACKGROUND:Sub-Saharan African (SSA) countries are experiencing rapid transitions with increased life expectancy. As a result the burden of age-related conditions such as neurodegenerative diseases might be increasing. We conducted a systematic review of published studies on common neurodegenerative diseases, and HIV-related neurocognitive impairment in SSA, in order to identify research gaps and inform prevention and control solutions. METHODS: We searched MEDLINE via PubMed, 'Banque de Donnees de Sante Publique' and the database of the 'Institut d'Epidemiologie Neurologique et de Neurologie Tropicale' from inception to February 2013 for published original studies from SSA on neurodegenerative diseases and HIV-related neurocognitive impairment. Screening and data extraction were conducted by two investigators. Bibliographies and citations of eligible studies were investigated. RESULTS: In all 144 publications reporting on dementia (n=49 publications, mainly Alzheimer disease), Parkinsonism (PD, n=20), HIV-related neurocognitive impairment (n=47), Huntington disease (HD, n=19), amyotrophic lateral sclerosis (ALS, n=15), cerebellar degeneration (n=4) and Lewy body dementia (n=1). Of these studies, largely based on prevalent cases from retrospective data on urban populations, half originated from Nigeria and South Africa. The prevalence of dementia (Alzheimer disease) varied between <1% and 10.1% (0.7% and 5.6%) in population-based studies and from <1% to 47.8% in hospital-based studies. Incidence of dementia (Alzheimer disease) ranged from 8.7 to 21.8/1000/year (9.5 to 11.1), and major risk factors were advanced age and female sex. HIV-related neurocognitive impairment's prevalence (all from hospital-based studies) ranged from <1% to 80%. Population-based prevalence of PD and ALS varied from 10 to 235/100,000, and from 5 to 15/100,000 respectively while that for Huntington disease was 3.5/100,000. Equivalent figures for hospital based studies were the following: PD (0.41 to 7.2%), ALS (0.2 to 8.0/1000), and HD (0.2/100,000 to 46.0/100,000). CONCLUSIONS: The body of literature on neurodegenerative disorders in SSA is large with regard to dementia and HIV-related neurocognitive disorders but limited for other neurodegenerative disorders. Shortcomings include few population-based studies, heterogeneous diagnostic criteria and uneven representation of countries on the continent. There are important knowledge gaps that need urgent action, in order to prepare the sub-continent for the anticipated local surge in neurodegenerative diseases
Spectral sensitivity of stare nystagmus and smooth pursuit
The visual system consists of several subsystems, which perform their task nearly independently of each other. One is the accessory-optic system, performing the gaze stabilisation by eye-nystagmus. In humans two kinds of nystagmus can be discriminated: stare nystagmus and look nystagmus (smooth pursuit). The best known example for stare nystagmus can be seen on a train journey. The vis-à-vis -staring out of the window- moves his eyes nystagmic. Without fixating any single object the eyes run over the landscape, most of the time following and bouncing back every now and then. In contrast, during look nystagmus single objects are fixated and pursued. Stare nystagmus is driven by the accessory-optic system, a set of subcortical nuclei, while cortical structures contribute to the look nystagmus. In order to find out which cones contribute to both kinds of nystagmus, we measured their spectral sensitivity. Two different instructions were given to the observers, leading to either stare or look nystagmus, respectively. Spectral sensitivity turned out to be different for look and stare nystagmus. Spectral sensitivity of stare nystagmus corresponds basically to the V(l)-function, indicating that there is no or only a minor contribution of the short wavelength cones. Look nystagmus has a higher sensitivity at short wavelengths, demonstrating a contribution of short wavelength cones
Spectral sensitivity of the accessory optic system of the pigeon.
When an animal is moving relative to its surroundings it can nevertheless stabilize the image on the retina, at least partially, by means of the large-held optomotor response. In the animal species investigated so far, this response has been found to be colour-blind as indicated by grey-matching tests, and to involve only photoreceptors sensitive in the long- wavelength region of the spectrum. Here we show that this rule also applies to pigeons, i.e. birds, a group not previously studied in this regard
Spectral sensitivity of the large field optomotor system in man
The visual system consist of several subsystems, which perform their task nearly independent of each other. One visual subsystem is the accessory-optic system, performing the gaze stabilisation by the nystagmus (physiological nystagmus). In humans there are two kinds of nystagmus: the stare nystagmus and the look nystagmus. The best know example for stare nystagmus in humans can be seen on a train journey. The vis-a-vis - staring out of the window - moves his eyes nystagmic. Without fixating any single item he runs his eyes over the landscape, most of the time following and bouncing back every now and then. This behavior is driven by the accessory-optic system, a set of subcortical nuclei, while cortical structures contribute to the look nystagmus. To know which cones contribute to the stare nystagmus, we measured its spectral sensitivity. Two instructions were given, leading to a stare and a look nystagmus, respectively. The spectral sensitivity of the eye movement differed for the two instructions. The stare nystagmus is dominated by the long wavelength sensitive cone, though a contribution of the medium wavelength sensitive cone can not be excluded. On the other hand, the contribution of the short wavelength cone to the look nystagmus is obvious. The optomotor system is colour-blind and uses the long wavelength part of the light spectrum in all examined species of insects, fish, amphibia, and reptiles. Man is to be added to this list. It is still unknown why the evolution ofthe visual system took the same direction in all these classes
- …